South Korea vs Sur: Previously treated cases tested for RR-/MDR-TB
South Korea
100.0%
in 2024
Sur
62.0%
in 2024
South Korea rank
1st
Sur rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- South Korea
- Sur
How they compare
South Korea currently reports 100.0% against 62.0% in Sur, a difference of 38.0%.
That makes South Korea's figure about 1.6 times Sur's.
The two have swapped places 8 times across 13 shared years of data; in 2011 it was South Korea ahead.
South Korea ranks 1st and Sur ranks 1st of 180 countries.
Across the 2 decades both report, South Korea averaged higher in 1 and Sur in 1.
Head to head by decade
| Decade | South Korea | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 55.5% | 59.6% | 4.1% | Sur |
| 2020s | 92.0% | 78.4% | 13.6% | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, South Korea or Sur?
- South Korea, at 100.0% against 62.0% in Sur as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between South Korea and Sur?
- 38.0%, with South Korea ahead.
- How many years of comparable data are there for South Korea and Sur?
- 13 years are reported by both, from 2011 to 2024.
- How do South Korea and Sur rank globally for previously treated cases tested for rr-/mdr-tb?
- South Korea ranks 1st and Sur ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.